Tenderwize
Retour à la recherche

Accord de remise non exclusif pour clindamycine et peroxyde de benzoyle

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Apr 27, 2027 · 157 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Clindamycin und Benzoylperoxid (ATC-Code: D10AF54).

52/100

Score d'opportunité

Needs reviewHigh complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

67 / 100

Facteurs de risque

The notice provides no estimated value, volumes, pricing assumptions, or guaranteed demand. The framework/open-house ar...

AOK Niedersachsen may replace the open-house agreements with exclusive rebate contracts during the stated period, and e...

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
AOK Niedersachsen. Die Gesundheitskasse.
Pays
Allemagne
CPV
33600000 - Pharmaceutical products
Date limite
Apr 27, 2027

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of a non-exclusive pharmaceutical rebate agreement for medicines containing clindamycin and benzoyl peroxide, ATC D10AF54.
  • Open-house participation by eligible pharmaceutical companies without a selection decision; identical contractual conditions apply to all participants.
Afficher le résumé complet

AOK Niedersachsen offers a non-exclusive open-house pharmaceutical rebate agreement for medicines combining clindamycin and benzoyl peroxide (ATC D10AF54) in Germany. Eligible pharmaceutical companies may join without a selection decision under uniform, non-negotiable conditions. Agreements may start monthly during the term, but all end no later than 30 June 2027 and may end earlier if exclusive rebate contracts enter into force. The estimated value is not stated. The initial joining deadline for a 1 July 2025 start was 28 May 2025; the structured final deadline is 27 April 2027, subject to the precise document-based receipt deadlines.

Risques

The notice provides no estimated value, volumes, pricing assumptions, or guaranteed demand. The framework/open-house ar...

AOK Niedersachsen may replace the open-house agreements with exclusive rebate contracts during the stated period, and e...

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The participant must be a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG, or a consortium of such pharmaceutical entrepreneurs, in relation to the offered...
  • A pharmaceutical entrepreneur marketing medicines within the scope of the AMG must have its registered seat in Germany, another EU Member State, or another EEA contracting state.
  • A local representative may participate only if it is itself a pharmaceutical entrepreneur within the meaning of Section 4(18) AMG for the relevant medicines.

Critères d'attribution

Lot 1

Price is the stated award criterion; no description or weighting is provided. The open-house model indicates that no competitive selection decision is intended.

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Clindamycin and Benzoyl Peroxide Pharmaceutical Rebate Agreement

Non-exclusive open-house rebate agreement under Section 130a(8) SGB V for medicines containing clindamycin and benzoyl peroxide, ATC D10AF54. Contracts are offered to all interested eligible pharmaceutical companies on identical terms without competitive selection or individual negotiation. The agreement can start on the first day of a month, has a maximum duration of 24 months, and ends no later than 30 June 2027. Lot information is based on structured tender data and the extracted XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Apr 27, 2027

Détails de la procédure

Date de publication
05 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
288357-2025

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy